Efficacy and Safety of Novel Multifunctional M10 CAR-T Cells in HIV-1-Infected Patients: A Phase I, Multicenter, Single-Arm, Open-Label Study

Investigators reported newly developed anti-HIV-1 CAR-T cells armed with endogenic broadly neutralizing antibodies (bNAbs) and the follicle-homing receptor CXCR5, termed M10 cells.